Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease
Open Access
- 15 July 2025
- journal article
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 12 (8) , 100259
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer DiseaseJAMA Neurology, 2025
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionAlzheimer's & Dementia, 2025
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- Donanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2021